Stock D4S DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Daiichi Sankyo Co., Ltd. Deutsche Boerse AG

Equities

D4S

JP3475350009

Market Closed - Deutsche Boerse AG
Other stock markets
 11:56:59 30/04/2024 BST 		5-day change 1st Jan Change
32.36 EUR +6.45% Intraday chart for Daiichi Sankyo Co., Ltd. +16.87% +32.68%
04-30 Remsons, Daiichi Infotainments Form Joint Venture MT
04-29 AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Remsons, Daiichi Infotainments Form Joint Venture
MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow
CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments
AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study
MT
Hipgnosis Songs Fund backs new Blackstone bid
AN
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
BU
Scholz pledges further support for the pharmaceutical industry
DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024
MT
AstraZeneca upbeat as cancer drugs underpin sales growth
AN
Daiichi Sankyo : Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB
PU
Daiichi Sankyo : FY2023 Reference Dat
PU
Transcript : Daiichi Sankyo Company, Limited, 2024 Earnings Call, Apr 25, 2024
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.
CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.
CI
Middle East Tensions Dent Asian Stock Markets
MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication
MT
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours
AQ
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. D4S Stock
  5. News Daiichi Sankyo Co., Ltd.